Litcius/Paper detail

Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer

Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, Wataru Hojo, Hironori Sakai, Ryo Takai, T Nose, Shinya Ohata, Yoshiaki Nagatani, Taiji Koyama, Akihito Kitao, Meiko Nishimura, Yoshinori Imamura, Naomi Kiyota, Kenichi Harada, Yugo Tanaka, Yasuko Mori, Hironobu Minami

2021Journal of Infection and Chemotherapy19 citationsDOIOpen Access PDF

Topics & Concepts

ImmunogenicityMedicineAdverse effectVaccinationCancerInternal medicineChemotherapyTiterImmunotherapyAntibodyAntibody titerImmune systemImmunologyCoronavirus disease 2019 (COVID-19)OncologyDiseaseInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchLymphadenopathy Diagnosis and AnalysisImmunotherapy and Immune Responses
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer | Litcius